Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Procainamide-induced lupus anticoagulant.

M R Heyman1, R H Flores, B B Edelman

  • 1Department of Medicine, University of Maryland School of Medicine, Baltimore 21201.

Southern Medical Journal
|July 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.

Annals of the rheumatic diseases·2003
Same author

"Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate.

Annals of the rheumatic diseases·2002
Same author

A 66-year-old man with hepatosplenomegaly and pancytopenia.

The American journal of the medical sciences·2002
Same author

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

The New England journal of medicine·1999
Same author

A 66-year-old woman with pneumonia and right heart failure.

Maryland medical journal (Baltimore, Md. : 1985)·1998
Same journal

The Five Essential Concepts of Developmental Medicine: A Medical Paradigm for People with Developmental Disabilities.

Southern medical journal·2026
Same journal

α-Gal Syndrome in the South: Why We Need Treatment Trials, Not Just Tick Prevention.

Southern medical journal·2026
Same journal

Association between Main Pancreatic Duct Size, Comorbidities, and Fistula Formation after Whipple Procedure for Pancreatic Cancer.

Southern medical journal·2026
Same journal

Impact of Temperature Variation on Patients with Acute Severe Asthma.

Southern medical journal·2026
Same journal

Assessing the Accuracy and Reliability of ChatGPT-4 to Answer Clinical EHR Messages in Sports Medicine.

Southern medical journal·2026
Same journal

Diagnostic Utility and Clinical Implications of Inpatient Fecal Occult Blood Testing.

Southern medical journal·2026
See all related articles

Patients taking procainamide may develop lupus anticoagulant, increasing thrombotic event risk. Screening these patients is recommended due to potential predisposition to thrombosis.

Area of Science:

  • Rheumatology
  • Pharmacology

Background:

  • Procainamide is a medication used to treat cardiac arrhythmias.
  • Lupus anticoagulant has been observed in patients using procainamide.

Observation:

  • The presence of lupus anticoagulant, with or without other lupus symptoms, is noted in procainamide users.
  • While bleeding episodes are rare, a potential for increased thrombotic events exists.

Findings:

  • Screening procainamide-treated patients for lupus anticoagulant may be warranted.
  • Further prospective studies are needed to determine the incidence of lupus anticoagulant and thrombosis frequency.

Implications:

  • This information could guide management strategies for patients on procainamide.

Related Experiment Videos

  • Early detection of lupus anticoagulant may help mitigate thrombotic risks.